Corrigendum to ‘Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant’ [Biomaterials, 128 (2021), 121159]

The authors have replaced the terms “AS03-L” and “AS03-like” with “AddaS03,” the full name of the InvivoGen adjuvant used as a positive control in the study, throughout the text and figures. The authors have also added the clarification: “AddaS03 is not identical to GSK’s trademarked AS03 adjuvant, and the results of our studies do not directly apply to GSK’s adjuvants.” Similarly, the terms “AS04-L” and “AS04-like” have been replaced with “Alum + MPLA” to describe an in-house adjuvant formulation consisting of alum and MPLA. The authors have added the clarification: “The Alum + MPLA prepared-in house is not identical to GSK’s trademarked AS04 adjuvant, and the results of RBD + Alum + MPLA administration do not directly apply to GSK’s AS04 adjuvants.” These corrections clarify that the authors’ study does not directly test GSK’s trademarked AS03 or AS04 adjuvants. These corrections do not alter any findings or conclusions reported in this article. The authors would like to apologize for any inconvenience caused.